For example, cabozantinib also inhibits c-MET and AXL, both known to be upregulated in RCC and to predispose to metastatic spread, contributing to its effectiveness in the front-line and refractory setting but also to its wide range of side effects in these populations. This evidence concerns the gene MET and renal cell carcinoma.